InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,166.40
(
0.51%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,089.55
(
0.13%
)
Post# of 252184
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ancientacid

Send PM Follow Ignore
Followers 33
Posts 2734
Boards Moderated 1
Alias Born 04/30/2010

ancientacid

Re: DewDiligence post# 242613

Friday, 06/17/2022 5:23:59 PM

Friday, June 17, 2022 5:23:59 PM

Post# of 252184
About the #2 on that list; Keytruda, keep an eye open on ways to find new synergetic paths to maintain an edge compared to biosimilars.

One might wonder if it's just a coincidence Merck offered Keytruda to a small swedish company in the oncology-sector for further study..?
https://bioinvent.com/media/press-releases/mfnsingle/?slug=bioinvent-announces-second-clinical-trial-collaboration-and-supply-agreement-to-evaluate-bi-1808-in-combination-with-keytruda-r-pembrolizumab-in-patients-with-advanced-solid-tumors-468bbc81

My posts are, will always be, and has always been in my own opinion. Do your own Due Diligence.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up